scholarly journals Diagnostic value of liver function tests in the detection of hepatic metastases in lung cancer patients.

Haigan ◽  
1985 ◽  
Vol 25 (5) ◽  
pp. 609-615
Author(s):  
Hiroshi Nishio ◽  
Takahiko Sakuma ◽  
Shinichiro Nakamura ◽  
Takeshi Horai ◽  
Harumichi Ikegami ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Liver Function ◽  
Cancer Patients ◽  
Hepatic Metastases ◽  
Liver Function Tests ◽  
Diagnostic Value ◽  
Lung Cancer Patients ◽  
Function Tests

scholarly journals The Role of CEA and Liver Function Tests in the Detection of Hepatic Metastases From Colo-Rectal Cancer

HPB Surgery ◽  
1990 ◽  
Vol 3 (1) ◽  
pp. 29-37 ◽  
Author(s):  
G. Bonfanti ◽  
Luigia Bombelli ◽  
F. Bozzetti ◽  
R. Doci ◽  
L. Gennari ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Liver Function ◽  
Liver Metastases ◽  
Predictive Value ◽  
Imaging Technique ◽  
Hepatic Metastases ◽  
Liver Function Tests ◽  
Good Prediction ◽  
Gamma Glutamyl Transpeptidase ◽  
Function Tests

Carcinoembryonic antigen and some liver function tests (alkaline phosphatase, gamma-glutamyl-transpeptidase, lactic dehydrogenase and cholinesterase) were evaluated in patients with primary colorectal cancer in order to define their role in the pre-operative detection of liver metastases.The records of 278 consecutive patients admitted to the Istituto Nazionale Tumori of Milan between January 1982 and December 1983 who were suffering from primary invasive colo-rectal cancer and who underwent laparotomy were retrospectively analyzed.At laparotomy, liver metastases were found in 38 pts (13.7%). Considering single tests, CEA was the most sensitive (71%); no single test was found to be reliably predictive, when the result was abnormal. On the contrary, the normal value of each test was associated with a good prediction.When we considered all the five tests together in the single patient their predictive value, when abnormal, proved to be quite good only if four or five results were abnormal. On the other hand, liver metastases in the presence of all normal tests were found only in two patients, so giving a negative predictive value of about 97%.So we conclude that, in the lack of an infallable imaging technique for liver evaluation, in the presence of all normal tests any other investigation on the liver could be avoided. However, when liver tests are pathologic, some other imaging technique should be performed in order to supply the surgeon with information about the extent and the spread of the metastases.

Diagnostic Effectiveness of Biochemical Liver-Function Tests, as Evaluated by Discriminant Function Analysis

1977 ◽  
Vol 23 (4) ◽  
pp. 627-630 ◽  
Author(s):  
Paul Phillip Sher
Keyword(s):  
Alkaline Phosphatase ◽  
Lactate Dehydrogenase ◽  
Discriminant Analysis ◽  
Liver Function ◽  
Function Analysis ◽  
Liver Function Tests ◽  
Diagnostic Value ◽  
Hepatic Disease ◽  
Stepwise Discriminant Analysis ◽  
Function Tests

Abstract I evaluated the diagnostic value of routinely ordered liver-function tests in 175 biopsy-proven cases of hepatic disease by use of stepwise discriminant analysis. The tests studied—total and "direct" bilirubin, alkaline phosphatase, lactate dehydrogenase, and aspartate aminotrans-ferase—correctly classified 45-73% of cases, depending on the homogeneity of the diagnostic groups. Aspartate aminotransferase and alkaline phosphatase were the best discriminators. When all tests were used in the most ho-mogeneous groups (tumors, cirrhosis, and hepatitis), there was a stepwise improvement in diagnostic accuracy from 51 to 73%.

Etiologic diagnosis of hepatic lesions in cancer patients value of ultrasound and liver function tests

1997 ◽  
Vol 21 (5) ◽  
pp. 366-371 ◽  
Author(s):  
Jean-Noel Bruneton ◽  
Charles Raffaelli ◽  
Bernard Padovani ◽  
Catherine Maestro ◽  
Patrick Chevallier ◽  
...  
Keyword(s):  
Liver Function ◽  
Cancer Patients ◽  
Liver Function Tests ◽  
Function Tests ◽  
Hepatic Lesions ◽  
Etiologic Diagnosis

scholarly journals Diagnostic value of α-enolase expression and serum α-enolase autoantibody levels in lung cancer

2018 ◽  
Vol 44 (1) ◽  
pp. 18-23 ◽  
Author(s):  
Lihong Zhang ◽  
Hongbin Wang ◽  
Xuejun Dong
Keyword(s):  
Lung Cancer ◽  
Lung Disease ◽  
Cancer Patients ◽  
Clinical Stage ◽  
Diagnostic Value ◽  
Smoking History ◽  
Lung Cancer Patients ◽  
Pathological Classification ◽  
Cancer Tissues ◽  
Antibody Levels

ABSTRACT Objective: To investigate the diagnostic value of α-enolase (ENO1) and serum ENO1 autoantibody levels in lung cancer. Methods: Immunohistochemistry staining and ELISA were performed to detect ENO1 expression in lung tissue and serum ENO1 autoantibody levels, respectively. Results: The expression of ENO1 was higher in lung cancer tissues than in benign lung disease tissues (p < 0.001). The proportion of lung cancer samples expressing ENO1 was not significantly different among the various pathological classification groups. The proportion of samples expressing ENO1 was higher in lung cancer patients in stages I/II than in those in stages III/IV (χ2 = 5.445; p = 0.018). The expression of ENO1 in lung cancer tissues was not associated with age, gender, or smoking history. Serum ENO1 antibody levels were significantly higher in the lung cancer group than in the benign lung disease and control groups (p < 0.001). The differences among the pathological classification groups were not statistically significant. Serum ENO1 antibody levels were also in lung cancer patients in stages I/II than in those in stages III/IV (p < 0.01). Serum ENO1 antibody levels were not associated with age, gender, or smoking history in lung cancer patients. The ROC curve representing the diagnosis of lung cancer based on ENO1 antibody levels had an area under the curve of 0.806. Conclusions: Our results suggest that high levels of ENO1 are associated with the clinical stage of lung cancer and that ENO1 expression and its serum autoantibody levels show diagnostic value in lung cancer.

Meta-Analysis of Microarrays: Diagnostic value of microRNA-21 as a Biomarker for Lung Cancer

2015 ◽  
Vol 30 (3) ◽  
pp. 282-285 ◽  
Author(s):  
Xinxin Meng ◽  
Chen Xiao ◽  
Yuguang Zhao ◽  
Lin Jia ◽  
Yang Tang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Sensitivity Analysis ◽  
Cancer Patients ◽  
Meta Analysis ◽  
Diagnostic Value ◽  
P Value ◽  
Significant Heterogeneity ◽  
Lung Cancer Patients ◽  
Potential Biomarker ◽  
Significant Difference

Background: MicroRNA-21 (miR-21) has previously been demonstrated as a potential biomarker in diagnosis of various human tumors. This meta-analysis was performed to evaluate the possibility of miR-21 as a biomarker for early detection of lung cancer. Methods: Relevant lung cancer-related miRNA microarray datasets were collected from the NCBI Gene Expression Omnibus (GEO) database and EBI ArrayExpress database up to February 2014. Quality control of the output data was estimated using Limma package and ExiMiR package in R. Standardized mean difference (SMD) with 95% confidence intervals (CIs) from selected datasets was pooled. Heterogeneity was assessed using Cochran's Q test and the I2 statistic, and a p value <0.0.05 or I2 >50% was defined as significant heterogeneity. Furthermore, sensitivity analysis was conducted to evaluate the stability of the pooled results. Four miRNA datasets (GSE24704, GSE17681, GSE27486 and GSE40738) from blood samples were selected, including 153 lung cancer patients and 109 healthy people. Results: The pooled results generated by random-effects model revealed that no significant difference was observed between case and control groups (SMD = 0.58; 95% CI, −0.04 to 1.19; p = 0.07) with significant heterogeneity (p = 0.0032, I2 = 78.2%; p = 0.06). Sensitivity analysis indicated that the results of the meta-analysis were stable. Conclusions: MiR-21 expression levels in whole blood and peripheral blood cells did not show significant differences between lung cancer patients and healthy controls, and it might be ineffective to measure miR-21 expression to achieve an early diagnosis of lung cancer.

Sign in / Sign up

Export Citation Format

Share Document